NOVOZYMES A/S SPONS.ADR 1 Financial Flexibility Index
NOVOZYMES A/S SPONS.ADR 1 financial flexibility index. NOVOZYMES A/S SPONS.ADR 1 (NZM) has a Financial Flexibility Index of 0.05x as of March 2026. Free cash flow of €260.20 Million (operating CF €167.10 Million minus capex €93.10 Million) represents 0% of total liabilities (€5.60 Billion). Explore NZM capex to operating cash flow ratio to see what proportion of operating cash flow is directed to capital expenditures.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of NOVOZYMES A/S SPONS.ADR 1 (2021–2025)
Financial flexibility index of NOVOZYMES A/S SPONS.ADR 1 from 2021 to 2025. Historical Financial Flexibility Index trend for NOVOZYMES A/S SPONS.ADR 1 across 5 annual periods. Check NZM cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
NOVOZYMES A/S SPONS.ADR 1 Financial Flexibility Index by Year (2021–2025)
NOVOZYMES A/S SPONS.ADR 1 financial flexibility index by year from 2021 to 2025. Year-by-year free cash flow to debt coverage for NOVOZYMES A/S SPONS.ADR 1. For the full cash flow conversion analysis, see NOVOZYMES A/S SPONS.ADR 1 cash flow conversion.
| Year | Flexibility Index | Free Cash Flow (EUR) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.31x | €1.69 Billion | €1.22 Billion | €5.49 Billion | ▼ -10.3% |
| 2024 | 0.34x | €1.38 Billion | €1.02 Billion | €4.02 Billion | ▼ -22.4% |
| 2023 | 0.44x | €832.90 Million | €557.10 Million | €1.88 Billion | ▼ -11.8% |
| 2022 | 0.50x | €925.52 Million | €537.65 Million | €1.85 Billion | ▲ +18.8% |
| 2021 | 0.42x | €712.90 Million | €546.17 Million | €1.69 Billion | — |